ANTI-SIRPalpha ANTIBODY

An antibody, CDRL2 technology, applied in the direction of antibodies, anti-tumor drugs, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the problem of no binding
CN112673023AActive Publication Date: 2021-04-16KOBE UNIV +1
13 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
KOBE UNIV
Publication Date
2021-04-16

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention addresses the problem of providing: an anti-SIRPalpha antibody which can be used as a tumor agent; and an anti-tumor agent containing the antibody as an active ingredient. The present invention is an antibody capable of binding specifically to human SIRPalpha to inhibit the binding between human SIRPalpha and CD47, the antibody containing (a) a light-chain CDRL1 comprising the amino acid sequence represented by SEQ ID NO: 1, (b) a light-chain CDRL2 comprising the amino acid sequence represented by SEQ ID NO: 2, (c) a light-chain CDRL3 comprising the amino acid sequence represented by SEQ ID NO: 3, (d) a heavy-chain CDRH1 comprising the amino acid sequence represented by SEQ ID NO: 4, (e) a heavy-chain CDRH2 comprising the amino acid sequence represented by SEQ ID NO: 5 and (f) a heavy-chain CDRH3 comprising the amino acid sequence represented by SEQ ID NO: 6, wherein a heavy-chain constant region is a heavy-chain constant region of human IgG4, and an phenylalanine residue at position-234, a leucine residue at position-235 and a serine residue at position-228, as numbered according to the EU index as in Kabat et. al., are substituted by an alanine residue, an alanine residue and a proline residue, respectively.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to an anti-SIRPα antibody useful for tumor therapy, and an antitumor agent containing the antibody. Background technique

[0002] SIRPα (SHPS-1) is a single transmembrane molecule of the Ig superfamily, and is present in myeloid cells such as macrophages, dendritic cells, and neutrophils, as well as glial cells (Non-Patent Document 1). The extracellular region is composed of one IgV domain and two IgC domains, and it has been reported that there are 10 variants of the IgV domain that binds to CD47 in humans (Non-Patent Document 2). On the other hand, the intracellular region contains immunoreceptor tyrosine-based inhibition motifs (ITIMs), which induce SHP-1 and SHP-2 binding to tyrosine phosphatases by binding to CD47. Send inhibitory signals.

[0003] As a physiological phenomenon resulting from SIRPα-CD47 interaction, it has been shown that CD47 on erythrocytes binds to SIRPα on macrophages and transmits a "don't eat ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More